University of St Andrews Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2008
NCT00864383
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

University of St Andrews

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypersensitivity (Phase 3)

Tuberculosis (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 6